Analysts from the hosting firm talked up their takeaways on biopharma from the J.P. Morgan (JPM) Healthcare Conference and looked ahead to 2024, anticipating a generally better year than those in the recent past.
Jazz Pharmaceuticals plc has disclosed macrocyclic orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.
In a global deal worth up to $770.5 million in up-front and milestone payments, Stevenage, U.K.-based Autifony Therapeutics Ltd. signed with Dublin-based Jazz Pharmaceuticals plc for two ion channel-targeting programs aimed at finding and developing new drugs for neurological disorders. Autifony will take selected candidates through preclinical development, while Jazz will cover clinical development, manufacturing, regulatory activities and commercialization.
Jazz Pharmaceuticals plc has described tricyclic phthalazines acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
South Korean biopharmaceutical firms are facing a harsher climate and an uphill battle both domestically and abroad, amid the larger economic downturn that has slowed everything from new drug approval to dealmaking. At the Global Pharma Key Opinion Leaders (GPKOL) 2023 Symposium held at the El Tower on Sept. 7 in Seocho-gu, Seoul, officials from the industry, government and academia gathered to discuss strategies on bouncing back from the lasting effects of the COVID-19 pandemic.
Jazz Pharmaceuticals plc has synthesized novel amine-substituted phthalazines and derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
HER2-targeting bispecific antibody zanidatamab, in development by Jazz Pharmaceuticals plc and Zymeworks Inc., produced better antitumor responses than current standard of care when used as a second-line treatment for biliary tract cancer (BTC) in a pivotal phase IIb study, bringing it closer to becoming the first therapy to target HER2-expressing BTC.
Now that Avadel Pharmaceuticals plc has final U.S. FDA approval for its narcolepsy drug Lumryz, the company has priced the sodium oxybate formulation to match the cost of competitor Xywav from Jazz Pharmaceuticals plc. Avadel said it plans to charge $64.67 per gram for Lumryz. The annual cost based a 9-gram dose would be about $212,441 per patient. Three daily dose levels, 6 grams, 7.5 grams and 9 grams, were evaluated during a phase III study the final approval was based on.
Jazz Pharmaceuticals plc has patented sulfonamides acting as orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.
An uptick in positive clinical data reported in recent months has helped nudge the BioWorld Biopharmaceutical Index (BBI) to its highest point this year. BBI is up by 15.58%, significantly higher than the 1.36% increase recorded at the end of August, just as statistically significant clinical results began to roll in from a number of biopharma companies.
